Senseonics Holdings, Inc. (SENS) Q2 2025 Earnings Call Transcript
Senseonics Holdings, Inc. (NYSE:SENS ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Frederick T. Sullivan - CFO, Secretary & Treasurer Mukul Jain - Chief Operating Officer Timothy T.
Senseonics Holdings (SENS) Reports Q2 Loss, Tops Revenue Estimates
Senseonics Holdings (SENS) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.03 per share a year ago.
Here's Why Senseonics (SENS) is Poised for a Turnaround After Losing 5.7% in 4 Weeks
The heavy selling pressure might have exhausted for Senseonics (SENS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Revisiting Senseonics After 4 Years: Still A Big Investment Opportunity
I share my recent interview with Senseonics CEO, Tim Goodnow and the CFO, Rick Sullivan. Senseonics has recently introduced a 365-day Continuous Glucose Monitoring system, aiming to disrupt a market dominated by short-term CGMs from DexCom, Abbott Laboratories, and Medtronic. The next 12 months will be crucial for Senseonics as they prove their technology and decide if they continue their commercial partnership with Ascensia, change partners to go solo.
Senseonics Holdings (SENS) Reports Q1 Loss, Tops Revenue Estimates
Senseonics Holdings (SENS) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.03 per share a year ago.
Senseonics (SENS) Upgraded to Buy: What Does It Mean for the Stock?
Senseonics (SENS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Senseonics Holdings, Inc. (SENS) Q4 2024 Earnings Call Transcript
Senseonics Holdings, Inc. (NYSE:SENS ) Q4 2024 Earnings Conference Call March 3, 2025 4:30 PM ET Company Participants Jeremy Feffer - Investor Relations, LifeSci Advisors Tim Goodnow - President and Chief Executive Officer Brian Hansen - President of CGM at Ascensia Diabetes Care Rick Sullivan - Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Matt Taylor - Jefferies Marie Thibault - BTIG Operator Good day, everyone, and welcome to today's Senseonics Fourth Quarter and Full Year 2024 Earnings Call. At this time, all participants are in a listen-only mode.
Senseonics Holdings (SENS) Reports Q4 Loss
Senseonics Holdings (SENS) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.03 per share a year ago.
Senseonics Holdings (SENS) Reports Q3 Loss, Tops Revenue Estimates
Senseonics Holdings (SENS) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.04 per share a year ago.
Senseonics Holdings, Inc. (SENS) Q3 2024 Earnings Call Transcript
Senseonics Holdings, Inc. (NYSE:SENS ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Jeremy Feffer - LifeSci Advisors Tim Goodnow - President and Chief Executive Officer Rick Sullivan - Chief Financial Officer Brian Hansen - President of CGM at Ascensia Diabetes Care Conference Call Participants Brian Langan - Morgan Stanley Vernon Bernardino - H.C. Wainwright Operator Good day, everyone, and welcome to the Senseonics Third Quarter 2024 Earnings Call.
Senseonics Stock Down Despite New FDA Approval for Eversense 365
SENS' latest regulatory clearance is likely to simplify diabetes management with the help of a long-lasting CGM system.
